REDWOOD CITY, Calif. and NEW YORK, Aug. 19, 2015 /PRNewswire/ -- Guardant Health and Flatiron Health today announced a strategic collaboration to build a proprietary, cloud-based information platform integrating liquid biopsy-based genomic testing with clinical treatment and outcomes data to support the accelerated development of targeted therapies for cancer.
The collaboration combines advanced clinical insights from the FlatironHealthOncologyCloudTM platform with genomic data from Guardant Health's Guardant360® liquid biopsy platform. The new platform will enable life science companies to uncover new molecular targets, expand clinical indications, reduce the time to recruit and select patients for trials, and longitudinally follow patients and their progress over time.
"Integrating clinical and genomic information has the potential to dramatically improve cancer treatment and advance therapy development," said Nat Turner, co-founder and chief executive officer, Flatiron Health. "Flatiron Health and Guardant Health's collective technology, oncology know-how and genomic expertise will deliver an advanced, cloud-based platform to enhance patient care."
Guardant Health and Flatiron Health will work together to develop products that integrate anonymous clinical treatment and outcomes data with genomic data for patients who have undergone testing with Guardant360®. The HIPAA-compliant information platform will be available to life science companies in the first half of 2016.
"Today, oncologists and patients are demanding new therapies matched to their underlying tumor genomics to improve cancer treatment," said Guardant Health CEO and co-founder Helmy Eltoukhy. "Guardant360 removes the tissue barrier to accessing this genomic information in real-time. When combined with Flatiron Health's clinical data, this will significantly accelerate timelines for drug development, enabling many new treatment options for millions of cancer patients."
About Flatiron Health, Inc.
Flatiron Health helps the oncology community deliver better, more efficient care by powering an innovative, cloud-based platform to address today's healthcare challenges. The Flatiron Health OncologyCloud™ platform includes the industry-leading electronic medical record for oncology, advanced analytics, patient portal and integrated billing management. Backed by Google Ventures, First Round Capital, LabCorp and others, Flatiron's industry-first technology platform and integrated suite of products deliver comprehensive support for cancer care providers and life science companies. For more information, please visit www.flatiron.com.
About Guardant Health
Guardant Health, headquartered in Redwood City, Calif., is focused on developing breakthrough diagnostics that can transform cancer from a silent killer into a manageable disease. The company is the liquid biopsy market leader and has raised $100 million in funding from Sequoia Capital, Khosla Ventures, Lightspeed Venture Partners and others. Its breakthrough pan-cancer blood test, Guardant360, digitally sequences billions of genomic data points to identify tumor genomic alterations at greater than 99.9999 percent specificity. Actionable genomic alterations and associated treatments are identified in about half the turnaround time – and with none of the risk – of tissue biopsies. The World Economic Forum named Guardant Health a 2015 Technology Pioneer.
Director, Communications & Enterprise Marketing
Mark de la Vina
Consort Partners for Guardant Health
SOURCE Guardant Health; Flatiron Health